grant application has been made to fund inclusion of measurement of urine albumen, plasma growth hormone, factor VIII-related antigen and N-acetyl-fl-D-glucosaminidase.
Dr. Sims wonders whether a therapy may only be effective in a particular sub-group of patients, and requests that detailed analyses in sub-groups should later be made. Whilst one can do this, it must only be a minor part of the analyses. In view of the very large number of sub-groups of patients which could be examined, the interpretation of any apparently statistically significant result in a particular sub-group will be difficult, as it could be a chance occurrence. The main analysis will be of patients according to their random allocations to diet alone, insulin or sulphonylurea, in relation to pre-determined end-points. Although there will be heterogeneity of patients in each group, the number of patients being studied is such that those in each allocation are expected to be similar populations and to be comparable.
Two major end-points have been chosen: (a) deaths from vascular events, sudden death or renal failure, (b) complication-free interval, including avoidance of death from any cause, heart attack, angina, renal failure, blindness, major stroke or amputation, each variable having strict definitions. These two end-points will be studied (1) between allocation to 'diet' and 'active therapy' (allocation to insulin or sulphonylurea) to determine whether attempting to improve blood glucose control will reduce the complications and (2) between 'insulin' and 'sulphonylurea' allocations to determine whether either has untoward deleterious side-effects. The stopping criterion will be a difference of three standard deviations, approximately p <0.01 in view of eight pre-determined yearly analyses between 1885 and 1992.
Yours sincerely, R. C. Turner, J. I. Mann and R. Peto
